Possible role of GABA-B receptor modulation in MPTP induced Parkinson's disease in rats

Experimental and Toxicologic Pathology

Volumn 67, Issue 2, 2015, Pages 211-217

  Tyagi, Ravi Kant ^a   Bisht, Rohit ^a   Pant, Jatin ^a   kumar, Puneet ^a   Majeed, Abu Bakar Abdul ^b   Prakash, Atish ^a,b  

^a ISF COLLEGE OF PHARMACY   (India)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

Antioxidant; CGP35348; GABA B; MPTP; Neuroinflammation

Indexed keywords

3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; BACLOFEN; CATALASE; GLUTATHIONE; INTERLEUKIN 1BETA; NITRITE; TUMOR NECROSIS FACTOR ALPHA; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; CYTOKINE; ORGANOPHOSPHORUS COMPOUND;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; GABAERGIC SYSTEM; LATENT PERIOD; LIPID PEROXIDATION; LOCOMOTION; MALE; MPTP-INDUCED PARKINSONISM; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; RAT; ROTAROD TEST; TASK PERFORMANCE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; WISTAR RAT;

RATTUS; RATTUS NORVEGICUS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BACLOFEN; CEREBRAL CORTEX; CORPUS STRIATUM; CYTOKINES; DISEASE MODELS, ANIMAL; GABA-B RECEPTOR AGONISTS; GABA-B RECEPTOR ANTAGONISTS; LIPID PEROXIDATION; MALE; MOTOR ACTIVITY; ORGANOPHOSPHORUS COMPOUNDS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; RATS, WISTAR; RECEPTORS, GABA-B; ROTAROD PERFORMANCE TEST;

EID: 84977781776     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2014.12.001     Document Type: Article

References (34)

1. Bisht R., Kaur B., Gupta H., Prakash A. Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats. Neurotoxicology 2014, 44:71-79.
2. Broen M., Duits A., Visser-Vandewalle V., Temel Y., Winogrodzka A. Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord 2011, 17:413-417.
3. Calon F., Morissette M., Rajput A.H., Hornykiewicz O., Bedard P.J., Di Paolo T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord 2003, 18:241-253.
4. B receptor activation in rat globus pallidus. Neuroscience 2002, 114:417-425.
5. Deisz R.A. The GABA(B) receptor antagonist CGP 55845A reduces presynaptic GABA(B) actions in neocortical neurons of the rat in vitro. Neuroscience 1999, 93(4):1241-1249.
6. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-74.
7. B receptors: structure and function. Prog Brain Res 2007, 160:43-57.
8. Gallagher D.A., O'Sullivan S.S., Evans A.H., Lees A.J., Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007, 22:1757-1763.
9. B receptors in the globus pallidus of parkinsonian monkeys. Exp Neurol 2011, 229:429-439.
10. + neurotoxicity in cerebellar granule cells by antioxidants. Cell Biol Int 2004, 28:373-380.
11. Gornall A.G., Bardwaill C.T., David M.M. Determination of serum proteins by means of biuret reaction. J Biol Chem 1949, 177:751-766.
12. Green L.C., Wagner D.A., Glgowski J., Skipper P.L., Wishnok J.S., Tannebaum S.R. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Ann Biochem 1982, 126:131-138.
13. Henchcliffe C., Beal M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008, 4:600-609.
14. Heneka M.T., Rodriguez J.J., Verkhratsky A. Neuroglia in neurodegeneration. Brain Res Rev 2010, 63:189-211.
15. Hsieh M.H., Ho S.C., Yeh K.Y., Pawlak C.R., Chang H.M., Ho Y.J., et al. Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced disease rat model. Pharmacol Biochem Behav 2012, 102:64-71.
16. Kalivendi S.V., Yedlapudi D., Hillard C.J., Kalyanaraman B. Oxidants induce alternative splicing of [α]-synuclein: implications for Parkinson's disease. Free Radic Biol Med 2010, 48:377-383.
17. B receptors in the rat globus pallidus. J Neurophysiol 2005, 94:1104-1114.
18. Kumar P., Kalonia H., Kumar A. Role of LOX/COX pathways in 3-nitropropionic acid induced Huntington's disease-like symptoms in rats: protective effect of licofelone. Br J Pharmacol 2011, 164:644-654.
19. + induced mitochondrial dysfunction and ROS production in vivo and in vitro. Food Chem Toxicol 2011, 49:271-280.
20. Lofrumento D.D., Saponaro C., Cianciulli A., De Nuccio F., Mitolo V., Nicolardi G., et al. MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. Neuroimmunomodulation 2011, 18:79-88.
21. Luck H. Catalase. Methods of enzymatic analysis 1971, 885-893. Academic Press, New York, NY. H.U. Bergmeyer (Ed.).
22. Meredith G.E., Rademacher D.J. MPTP mouse models of Parkinson's disease: an update. J Parkinsons Dis 2011, 1:19-33.
23. Moore D.J., West A.B., Dawson V.L., Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005, 28:57-87.
24. Nambu A. Seven problems on the basal ganglia. Curr Opin Neurobiol 2008, 18:595-604.
25. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1986, Academic Press, London.
26. B receptors are heteromultimers with a family of auxiliary subunits. Nature 2010, 465:231-235.
27. Seet R.C., Lee C.Y., Lim E.C., Tan J.J., Quek A.M., Chong W.L., et al. Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radic Biol Med 2010, 48:560-566.
28. Steeves T.D., Miyasaki J., Zurowski M., Lang A.E., Pellecchia G., Van Eimeren T., et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009, 132:1376-1385. (vol).
29. Stocchi F., Nordera G., Marsden C.D. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 1997, 20:95-115.
30. Stocchi F., Vacca L., Berardelli A., Onofrj M., Manfredi M., Ruggieri S. Dual dopamine agonist treatment in Parkinson's disease. J Neurol 2003, 250(7):822-826.
31. Tieu K. A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med 2011, 1(Sep):a009316.
32. Uribe V., Wong B.K., Graham R.K., Cusack C.L., Skotte N.H., Pouladi M.A., et al. Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6 deficient mice. Hum Mol Genet 2012, 1:1954-1967.
33. Wills E.D. Mechanism of lipid peroxide formation in animal tissues. Biochemical J 1966, 99:667-676.
34. Zawada W.M., Banninger G.P., Thornton J., Marriott B., Cantu D., Rachubinski A.L., et al. Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. J Neuroinflammation 2011, 5(8):129.